Biogen CEO to step down as company pulls back on Alzheimer’s drug
Future of Aduhelm was in doubt after Medicare restricted coverage to clinical trials
European regulators cast doubt on Biogen Alzheimer’s treatment
EMA vote deals a setback to controversial $56,000-a-year treatment
Alzheimer’s drug hopes see Biogen shares surge 27%
Pharma group resurrects pipeline therapy it abandoned as ineffective earlier this year
Sale of psoriasis drug Otezla will clear way for €74m Celgene deal
Bristol-Myers Squibb’s acquisition of Celgene goes ahead after Amgen pays €13.4bn for drug
YOU MAY ALSO LIKE...
Crosswords & Puzzles
Crosswords & puzzles to keep you challenged and entertained
Stardust
Inquests into the nightclub fire that led to the deaths of 48 people
Common Ground
How does a post-Brexit world shape the identity and relationship of these islands
Family NoticesOpens in new window
Weddings, Births, Deaths and other family notices